| Name | Title | Contact Details |
|---|
Diversified Clinical Services is a privately held corporation headquartered in Jacksonville, Florida, with offices in Tustin, CA and the Woodlands, TX. The company was formed as a result of a merger between Diversified Therapy and Praxis Clinical
TRIMEDX is a technology-enabled, clinical asset management company, anchored on a strong foundation of clinical engineering, exclusively serving the healthcare community. As the largest independent technology-enabled clinical asset management company in the U.S., TRIMEDX provides strategic planning for - and management of - clinical assets to drive reductions in operational expenses, free up capital for new strategic initiatives, and deliver improved safety and cyber protection. Headquartered in Indianapolis, Indiana, TRIMEDX was built by providers, for providers, and leverages a history of expert clinical engineering to manage over $30 billion in clinical assets across thousands of locations. Our programs include flexible, yet comprehensive management of all patient-based technology, including biomedical, imaging, laboratory, and specialty equipment. Key features of our programs include: • Client Experience Center • Parts and Service Procurement Center • Regulatory Compliance Team • Computerized Maintenance Management System • Equipment Lifecycle Management In September of 2012, TRIMEDX was recognized by Modern Healthcare Magazine as the #1 Clinical Equipment Maintenance Contractor.
AlwaysCare Benefits is a Baton Rouge, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Headquartered in Vancouver, BC, BZAM Cannabis is a multi-licensed Canadian cannabis producer focused on branded consumer goods, cultivation, processing and people.
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.